bioAffinity Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From bioAffinity Technologies, Inc.
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
- In Vitro Diagnostics
- Laboratory Testing Services
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
- OncoSelect Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.